21
Participants
Start Date
June 1, 2021
Primary Completion Date
April 25, 2025
Study Completion Date
April 25, 2025
BB2121
CAR T Cell Therapy
CC-220
Cereblon (CRBN) E3 ligase modulatory compound (CELMoD)
BMS-986405
gamma secretase inhibitor (GSI)
Local Institution - 117, Birmingham
New York University Langone, New York
Local Institution - 110, New York
Local Institution - 118, Philadelphia
Local Institution - 111, Charlotte
Local Institution - 104, Atlanta
Local Institution - 120, Atlanta
Local Institution - 201, Pamplona
Local Institution - 202, Salamanca
Local Institution - 103, Nashville
Local Institution - 114, Chicago
Local Institution - 107, Houston
Local Institution - 113, San Francisco
Local Institution - 101, Jacksonville
Local Institution - 108, Boston
Local Institution - 124, Boston
Local Institution - 109, Hackensack
Lead Sponsor
Celgene
INDUSTRY